BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$
—Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.
Johnny is hearing from his very reliable sources that the FDA is shortly going to release the good news that BMSN shareholders have been waiting for, APPROVAL for HemaXellerate to move on and proceed with clinical trials. Wait for official word and then enjoy the ride shareholders of BMSN, check back for more updates!
Biotech Stock Share Price Rise Or Fall Projections For Week Of February 25th To March 1st 2013
Target: 2,00 - 3,00 + Longtermtarget $$$ Dollars
Mit Zitat antworten Beitrag zum Zitieren auswählen Direkt antworten
BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$ —Alert__BREAKING>>> Beitrag #2
BMSN $ NEWS - BMSN will shoot over 0,10 after FDA Approval $$$
sierraworldequityreview.blogspot.de/2013/03/new-price-targetbio-matrix-scientific_2.html?m=1
$$$ Alert__BREAKING>>>>Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.
Sierra World Equity Review
Saturday, March 2, 2013
New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review
HEADLINE: New Price Target_Bio-Matrix Scientific Group (BMSN) To Run To 10 Cents Following Upcoming FDA Approval To Move Forward With HemaXellerate Predicts Sierra World Equity Review. That's Just The Tip Of The Iceberg, Dollarland Coming Upon Orphan Drug Designation Forecasts Sierra World Equity Review.
For the latest updates on these stocks and to learn more about Sierra go to:
Sierra's Hot Stock Website
2013 FDA Calender
Latest Clinical Trial Results
A list of all Sierra's accurate calls and predictions that came true:
All These Came True, Accurate Sierra Are You Believer Yet!!!
Accurate call after accurate call, smart, single supermodel Sierra is SMOKING HOT in her predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Famous for her HEADLINERS, Sierra made more correct calls in the last 9 months than all other Stock Reviews COMBINED.
Check back for instant updates....Independent Sierra World Equity Review currently hold no positions in any of the stocks listed above......be the first to read Sierra's new posts, follow Sierra on Twitter
Sierra World Equity Review at 1:02 AM
BMSN $ STRONG BUY $ Target: 1,00+ US Dollars
< Message edited by Bullrider77 -- 3/2/2013 3:40:26 PM >
Mit Zitat antworten Beitrag zum Zitieren auswählen Direkt antwort
BMSN - NEWS $$$ FDA 2013 Calender and Clinical Trial Results $$$ —Alert__BREAKING>>> Beitrag #3
Daumen hoch BMSN. BMSN. BMSN. NEWS. NEWS. Big big NEWS soon IMO. SATURDAY, FEBRUARY 16, 2013
BMSN - Longterm Target. 1,00+ US$$$ Dollars